台湾慢性淋巴细胞白血病患者第二原发恶性肿瘤风险:癌症登记研究
该全国性回顾性队列研究利用台湾癌症登记库,分析了1991至2020年诊断的2702例慢性淋巴细胞白血病(CLL)患者第二原发恶性肿瘤(SPM)风险。总体SPM风险升高(SIR 1.14,95%CI 1.00-1.29),5年累积发生率6.53%,上皮性皮肤癌和膀胱癌风险显著增加,且风险在诊断后5年内最高。
要点
- 亚洲CLL患者总体SPM风险轻度升高,SIR 1.14。
- 上皮性皮肤癌和膀胱癌风险显著增加,需重点监测。
- SPM风险在CLL诊断后5年内最高,随后下降。
核心结论
- 亚洲CLL患者SPM风险谱与西方不同,总体风险轻度升高,膀胱癌风险突出。
研究设计与样本
- 全国性回顾性队列研究,纳入台湾癌症登记库1991-2020年诊断的2702例CLL患者。
主要发现
- 总体SPM风险升高,SIR 1.14(95%CI 1.00-1.29),5年累积发生率6.53%。
- 上皮性皮肤癌风险升高,SIR 2.55(95%CI 1.60-3.86)。
- 膀胱癌风险升高,SIR 1.99(95%CI 1.06-3.41)。
- 年轻女性乳腺癌风险降低,SIR 0.29(95%CI 0.06-0.85)。
- 诊断后5年内SPM风险最高,SIR 2.72(95%CI 2.27-3.22),之后降低,SIR 0.67(95%CI 0.56-0.81)。
临床怎么用
- 对亚洲CLL患者应加强皮肤癌和膀胱癌的针对性筛查。
- SPM监测应重点关注CLL诊断后的前5年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While second primary malignancies (SPMs) in Western patients with chronic lymphocytic leukaemia (CLL) are well documented, data from Asian populations remain limited. This nationwide, retrospective cohort study assessed SPM risk in 2702 CLL patients diagnosed in Taiwan between 1991 and 2020 using the Taiwan Cancer Registry. Standardized incidence ratios (SIRs), absolute excess risks and cumulative incidences were calculated relative to the general population, stratified by sex, age, latency and treatment. The overall SPM risk was elevated (SIR, 1.14, 95% confidence interval [CI], 1.00-1.29), with a 5-year cumulative incidence of 6.53%. Notably increased risks were observed for epithelial skin cancer (SIR, 2.55; 95% CI, 1.60-3.86) and urinary bladder cancer (SIR, 1.99; 95% CI, 1.06-3.41). A lower risk of breast cancer was detected among younger women (SIR, 0.29; 95% CI, 0.06-0.85). SPM risk was highest within 5 years of CLL diagnosis (SIR, 2.72; 95% CI, 2.27-3.22) and then decreased thereafter (SIR, 0.67; 95% CI, 0.56-0.81). These findings reveal a distinct SPM risk profile among Asian CLL patients, particularly the excess risk of bladder cancer, underscoring the importance of tailored surveillance strategies for this population.
引用
- Lee YW, Chiang CJ, Lin YC, et al. Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study. Br J Haematol. 2026. PMID: 41608915. doi:10.1111/bjh.70353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。